Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer

F. Grossi, M. C. Pennucci, J. Serrano, C. Frola, C. Mereu, T. Scolaro, G. B. Ratto, L. Tixi, A. Ardizzoni

Research output: Contribution to journalArticle

Abstract

Background: The aim of this study was to assess whether patients with truly unresectable (bulky extracapsular N2, T4 for tracheobronchial angle or mediastinal organ invasion) stage III non-small cell lung cancer (NSCLC), as proven by cervical mediastinoscopy supplemented or not by left anterior mediastinoscopy and fiberoptic bronchoscopy or thoracotomy, could become resectable after induction cisplatin-containing chemotherapy. In addition, we studied the value of preoperatory magnetic resonance imaging (MRI), in evaluating the probability of achieving a radical resection after neoadjuvant chemotherapy. Patients and Methods: Sixteen consecutive untreated stage III NSCLC patients were enrolled in the study. All the patients received two cycles of combination chemotherapy including cisplatin 100-120 mg/m intravenously (i.v.) days 1 and 22 and vinorelbine 30 mg/m i.v. days 1, 8, 15, 22 and 28 or vinblastine 5 mg/m2 i.v. days 1, 8, 15, 22 and 28. Thoracotomy was planned, after chemotherapy, for all non-progressive patients. No other treatment after surgery was devised following radical resection and patients with residual disease after surgery received standard post-operative radiotherapy. Response to treatment was evaluated by thorax CT and MRI two weeks after the last administration of chemotherapy. Results: The overall complete resection rate was 38% (6 out of 16 patients). MRI was predictive of complete resectability in 80% of cases. In fact, 6 patients judged resectable were completely resected, 3 patients judged unresectable underwent only explorative thoracotomy or incomplete resection while MRI was unpredictive only in one case. The most important chemotherapy-related toxicity was hematological: eight patients (50%) had grades III-IV leukopenia. Conclusion: These results indicate that preoperative second generation cisplatin-based chemotherapy can make resectable truly unresectable stage III NSCLC patients in only 38% of cases and that MRI is a reliable tool for assessment of radical resection probability after neoadjuvant chemotherapy.

Original languageEnglish
Pages (from-to)3519-3524
Number of pages6
JournalAnticancer Research
Volume22
Issue number6 B
Publication statusPublished - Nov 2002

Keywords

  • Combined treatment
  • Magnetic resonance imaging
  • Neoadjuvant chemotherapy
  • Non-small cell lung cancer
  • NSCLC staging
  • Surgery

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Grossi, F., Pennucci, M. C., Serrano, J., Frola, C., Mereu, C., Scolaro, T., Ratto, G. B., Tixi, L., & Ardizzoni, A. (2002). Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer. Anticancer Research, 22(6 B), 3519-3524.